東大発新興、次世代遺伝子治療を開発へ　治験29年メド | AN Venture Partners

東大発新興、次世代遺伝子治療を開発へ　治験29年メド

MediaPortfolio Companies

東大発新興、次世代遺伝子治療を開発へ　治験29年メド

February 27, 2024

Crystalys Therapeutics Advances Phase 3 Trials of Dotinurad for the Treatment of Gout with Dosing of First Patient

Press Release

Portfolio Companies

Crystalys Therapeutics Advances Phase 3 Trials of Dotinurad for the Treatment of Gout with Dosing of First Patient

San Diego, October 21, 2025

AN Venture Partner’s New Portfolio Company, Crystalys Therapeutics Launches with $205M Series A Financing to Advance Next-Generation Gout Treatment

Press Release

Portfolio Companies

AN Venture Partner’s New Portfolio Company, Crystalys Therapeutics Launches with $205M Series A Financing to Advance Next-Generation Gout Treatment

San Diego, September 30, 2025

Privacy Policy

This website uses Google Analytics cookies for access analysis only. The collected data is used solely for improving the website and is handled appropriately. By clicking "AGREE", you consent to the use of cookies.

Privacy Policy

This website uses Google Analytics cookies for access analysis only. The collected data is used solely for improving the website and is handled appropriately. By clicking "AGREE", you consent to the use of cookies.